Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting | Zendy

Courtney M. Yuen | Zendy; Arman Majidulla | Zendy; Maria Jaswal | Zendy; Nauman Safdar | Zendy; Amyn A. Malik | Zendy; Aamir Khan | Zendy; Mercedes C. Becerra | Zendy; Salmaan Keshavjee | Zendy; Chunling Lu | Zendy; Hamidah Hussain | Zendy

Open Access

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting

Author(s) -

Courtney M. Yuen,

Arman Majidulla,

Maria Jaswal,

Nauman Safdar,

Amyn A. Malik,

Aamir Khan,

Mercedes C. Becerra,

Salmaan Keshavjee,

Chunling Lu,

Hamidah Hussain

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa1835

Subject(s) - rifapentine , isoniazid , medicine , tuberculosis , indirect costs , cost–benefit analysis , chemoprophylaxis , total cost , emergency medicine , environmental health , pediatrics , surgery , latent tuberculosis , mycobacterium tuberculosis , business , ecology , accounting , pathology , biology

Successful delivery and completion of tuberculosis preventive treatment are necessary for tuberculosis elimination. Shorter preventive treatment regimens currently have higher medication costs, but patients spend less time in care and are more likely to complete treatment. It is unknown how economic costs of successful delivery differ between longer and shorter regimens in high-tuberculosis-burden settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research